Clinical trial
REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients
NCT05396807 is registered in ClinicalTrials.gov with University of Rome Tor Vergata as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients
- Lead sponsor
- University of Rome Tor Vergata
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- March 21, 2023
- Completion date
- November 25, 2024
- Enrollment
- 106 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic colon cancer